Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 17/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | CCR4 | P51679 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597969 | 1.00 | CCR5 (0.50) | CCR5RIPK1CCR4KCNH2PIK3C3 | |
| SCHEMBL5573756 | 0.87 | CCR5 (0.51) | CCR5CCR4KCNH2 | |
| SCHEMBL4652438 | 0.87 | CCR5 (0.52) | CCR5CCR4KCNH2PIK3C3 | |
| SCHEMBL4596594 | 0.87 | CCR5 (0.42) | CCR5CCR4KCNH2 | |
| SCHEMBL4652432 | 0.87 | CCR5 (0.52) | CCR5CCR4KCNH2PIK3C3 | |
| SCHEMBL5573761 | 0.87 | CCR5 (0.51) | CCR5CCR4KCNH2 | |
| SCHEMBL3754248 | 0.86 | CCR5 (0.53) | CCR5CCR4KCNH2 | |
| SCHEMBL3754244 | 0.86 | CCR5 (0.53) | CCR5CCR4KCNH2 | |
| SCHEMBL5575468 | 0.78 | CCR5 (0.41) | CCR5CCR4KCNH2 | |
| SCHEMBL4597078 | 0.78 | CCR5 (0.41) | CCR5CCR4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924265-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | Genzyme Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | CCR5 1/4885RIPK1 439/4885CCR4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.